Trials / Completed
CompletedNCT05794581
A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes
A Randomized, Double-Blind, Placebo and Comparator-Controlled Crossover Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Carmot Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study will be conducted primarily to evaluate the effects of CT-868 on glucose homeostasis in participants with Type 1 Diabetes Mellitus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CT-868 | CT-868 |
| DRUG | Placebo | Placebo as SC Injection |
| DRUG | Victoza | Victoza as active comparator as SC Injection |
Timeline
- Start date
- 2023-03-21
- Primary completion
- 2024-03-06
- Completion
- 2024-04-06
- First posted
- 2023-04-03
- Last updated
- 2024-12-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05794581. Inclusion in this directory is not an endorsement.